Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

10/21/2021 | 04:22pm EST

Item 7.01. Regulation FD Disclosure.

BeiGene, Ltd. ("BeiGene") expects to announce its financial results for the three and nine months ended September 30, 2021 on Thursday, November 4, 2021 after the close of U.S. financial markets.

Item 8.01. Other Events.

On October 20, 2021, BeiGene and Nanolek, a biopharmaceutical company specializing in the production of import-substituting and innovative drugs in Russia, announced that BRUKINSA® (zanubrutinib) has received approval from the Russia Ministry of Health for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. BeiGene and Nanolek entered into an exclusive distribution agreement for Nanolek to commercialize BRUKINSA in the Russian Federation. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

   Exhibit No.            Description

       99.1               Press Release titled "BeiGene and Nanolek Announce Approval in Russia for
                          BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or
                          Refractory Mantle Cell Lymphoma", issued by BeiGene, Ltd. on October 20,
                          2021.

       104                The cover page from this Current Report on Form 8-K, formatted in Inline
                          XBRL



--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about BEIGENE, LTD.
12/03China's Medical Products Regulator Approves BeiGene's Sylvant for Multicentric Castlema..
MT
12/03Beigene Grants Share Options to Five Employees
MT
12/03China Includes Three Beigene Drugs to New National Reimbursement Drug List
MT
12/02BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT« (Siltuximab for Injection) i..
BU
12/02BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tis..
BU
12/02BeiGene Announces Inclusion in the China National Reimbursement Drug List of Tislelizum..
CI
12/02BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
BU
12/02BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
CI
11/30BeiGene to Raise $3.5 Billion in Shanghai IPO; Shares Jump 3%
MT
11/30BeiGene Prices Shanghai Stock Exchange IPO
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations